Fiche publication
Date publication
octobre 2024
Journal
United European gastroenterology journal
Auteurs
Membres identifiés du Cancéropôle Est :
Pr PEYRIN-BIROULET Laurent
Tous les auteurs :
Schreiber S, Feagan BG, Louis E, Hisamatsu T, Hibi T, Dron L, Jamoul C, Patel H, Harris K, Taliadouros V, Oortwijn A, Peyrin-Biroulet L
Lien Pubmed
Résumé
Filgotinib is an oral, once-daily, Janus kinase 1 preferential inhibitor approved for treatment of ulcerative colitis (UC) following the phase 2b/3 SELECTION trial. Identification of patient populations and factors associated with long-term treatment response trajectories may improve UC management.
Mots clés
Janus kinase 1 inhibitor, clinical trials, comprehensive disease control, filgotinib, inflammatory bowel disease, symptom trajectories, ulcerative colitis
Référence
United European Gastroenterol J. 2024 10 25;:
